

Table S1 Comparison of population characteristics between patients according to PET/CT status

Characteristics	Total (N=703)	Non-PET/CT (N=349)	PET/CT (N=354)	Comparison (P value)
Sex, n (%)				0.16
Male	468 (66.6)	239 (68.5)	229 (64.7)	
Female	235 (33.4)	110 (31.5)	125 (35.3)	
Age at diagnosis [†] (years)				0.002
Mean (SD)	68.97 (8.301)	69.84 (8.768)	68.12 (7.733)	
Median	70.00	71.00	69.00	
5th; 95th percentile	54.00; 81.00	54.50; 82.00	54.00; 79.00	
Age category, n (%)				0.34
<65 years	183 (26.0)	88 (25.2)	95 (26.8)	
≥65 years	520 (74.0)	261 (74.8)	259 (73.2)	
Year of diagnosis, n (%)				0.43
2018	117 (16.6)	61 (17.5)	56 (15.8)	
2019	255 (36.3)	121 (34.7)	134 (37.9)	
2020	185 (26.3)	92 (26.4)	93 (26.3)	
2021	143 (20.3)	72 (20.6)	71 (20.1)	
2022	3 (0.4)	3 (0.9)	0 (0.0)	
Smoking status, n (%)				0.01
Smoker	368 (52.3)	177 (50.7)	191 (54.0)	
Former smoker	252 (35.8)	28 (8.0)	32 (9.0)	
Non-smoker	60 (8.5)	125 (35.8)	127 (35.9)	
Unknown	23 (3.3)	19 (5.4)	4 (1.1)	
Performance status, n (%)				<0.001
0	149 (21.2)	46 (13.2)	103 (29.1)	
1	395 (56.2)	184 (52.7)	211 (59.6)	
2	106 (15.1)	73 (20.9)	33 (9.3)	
3	19 (2.7)	19 (5.4)	0 (0.0)	
Not evaluated	34 (4.8)	27 (7.7)	7 (2.0)	
Type of tumor, n (%)				<0.001
Adenocarcinoma	242 (34.4)	93 (26.6)	149 (42.1)	
NOS	40 (5.7)	27 (7.7)	10 (2.8)	
Adenosquamous carcinoma	15 (2.1)	5 (1.4)	13 (3.7)	
Squamous cell carcinoma	390 (55.5)	215 (61.6)	175 (49.4)	
Other non-squamous	16 (2.3)	9 (2.6)	7 (2.0)	

Table S1 (continued)

Table S1 (continued)

Characteristics	Total (N=703)	Non-PET/CT (N=349)	PET/CT (N=354)	Comparison (P value)
Stage, n (%)				<0.001
IIIA	284 (40.4)	116 (33.2)	168 (47.5)	
IIIB	287 (40.8)	153 (43.8)	134 (37.9)	
IIIC	132 (18.8)	80 (22.9)	52 (14.7)	
TNM (T stage), n (%)				<0.001
T1a	5 (0.7)	3 (0.9)	2 (0.6)	
T1a(mi)	1 (0.1)	0 (0.0)	1 (0.3)	
T1b	14 (2.0)	2 (0.6)	12 (3.4)	
T1c	23 (3.3)	10 (2.9)	13 (3.7)	
T2a	62 (8.8)	20 (5.7)	42 (11.9)	
T2b	50 (7.1)	18 (5.2)	32 (9.0)	
T3	177 (25.2)	78 (22.3)	99 (28.0)	
T4	371 (52.8)	218 (62.5)	153 (43.2)	
TNM (N stage), n (%)				0.28
N0	71 (10.1)	35 (10.0)	36 (10.2)	
N1	105 (14.9)	43 (12.3)	62 (17.5)	
N2	345 (49.1)	174 (49.9)	171 (48.3)	
N3	180 (25.6)	96 (27.5)	84 (23.7)	
N-not available	1 (0.1)	0 (0.0)	1 (0.3)	
NX	1 (0.1)	1 (0.3)	0 (0.0)	
Treatment regimens [‡] , n (%)				<0.001
Without intervention	153 (21.8)	106 (30.4)	47 (13.3)	
Chemoradiotherapy (platinum-based)	65 (9.2)	29 (8.3)	36 (10.2)	
Surgery	132 (18.8)	42 (12.0)	90 (25.4)	
Chemotherapy	303 (43.1)	141 (40.4)	162 (45.8)	
Radiotherapy	50 (7.1)	31 (8.9)	19 (5.4)	

[†], age at diagnosis C34 morphologically; [‡], selection of the most common interventions—first treatment. PET/CT, positron emission tomography and computed tomography; N, total number of patients; SD, standard deviation; NOS, non-small cell lung cancer-not otherwise specified; TNM, tumor, node and metastasis classification system.

Table S2 Summary of patients according to PET/CT status across centers

Center	PET/CT (N=354)
Center 1	3 (2.8%)
Center 2	48 (44.4%)
Center 3	74 (74.0%)
Center 4	32 (27.6%)
Center 5	41 (57.7%)
Center 6	99 (69.7%)
Center 7	57 (96.6%)

PET/CT, positron emission tomography and computed tomography; N, total number of patients.

Table S3 Proportion of PET/CT examinations in different years

Year*	2018 (N=117)	2019 (N=255)	2020 (N=185)	2021 (N=143)
Non-PET/CT	61 (52.1)	121 (47.5)	92 (49.7)	72 (50.3)
PET/CT	56 (47.9)	134 (52.5)	93 (50.3)	71 (49.7)

*, 2022 is not provided because only three patients were diagnosed in 2022. PET/CT, positron emission tomography and computed tomography; N, total number of patients.